Abstract

The activation of factor X by VIIa/TF and the Xa-dependent inhibition of the enzyme complex by tissue factor pathway inhibitor (TFPI) are considered primary steps in the initiation of coagulation. IX activation by VIIa/TF is considered to contribute catalyst necessary for further Xa production in the ensuing amplification phase. We have investigated Xa and IXabeta production by VIIa-TF in a system reconstituted with both X and IX and the principal physiologic inhibitors of this pathway TFPI and antithrombin III (AT). Kinetic studies without inhibitors established that IX and X functioned as competitive alternate substrates for VIIa/TF with similar kinetic constants. When both IX and X were present, TFPI significantly inhibited the extent of formation of either IXabeta or Xa. In contrast, AT rapidly depleted active Xa with a small effect on IXabeta formation. When both AT and TFPI were present, active IXabeta formation significantly exceeded the formation of active Xa regardless of the VIIa/TF concentration. These findings could be quantitatively accounted for by a model encompassing the kinetics of the individual activation and inhibition steps. Active Xa formation by this pathway is regulated in a principal way by its rapid inactivation by AT. In contrast, the Xa-dependent inhibitory reactions of TFPI play a primary role in limiting zymogen consumption and the formation of active IXabeta. These regulatory phenomena yield active IXabeta as a major rather than secondary product of VIIa/TF. Our findings raise the possibility that IXabeta produced by the extrinsic pathway, and its ability to function within the intrinsic Xase complex to activate X may play a significant role in producing Xa necessary for both the initiation and sustained phases of the procoagulant response following vascular damage.

Highlights

  • The activation of factor X by VIIa/TF and the Xa-dependent inhibition of the enzyme complex by tissue factor pathway inhibitor (TFPI) are considered primary steps in the initiation of coagulation

  • Whereas the reactions of the Kunitzlike inhibitory domains of TFPI involve tight-binding reversible cles composed of 75% (w/w) L-␣-phosphatidylcholine and 25% (w/w) L-␣-phosphatidylserine; PfIXa, methysulfonyl-D-cyclohexylglycyl-glycyl-L-arginyl-7-amino-4-methylcoumarin; Recombinant tick anticoagulant peptide (rTAP), recombinant tick anticoagulant peptide; SpXa, methoxycarbonyl-D-cyclohexylglycyl-glycylarginyl-p-nitroanilide; SpIXa, methysulfonyl-D-cyclohexylglycyl-glycylarginyl-p-nitroanilide; TF-PC, PC vesicles containing ϳ1 effective TF/ vesicle; TF-PC and 25% (w/w) PS (PCPS), PCPS vesicles containing ϳ1 effective TF/vesicle; TFPI, recombinant full-length tissue factor pathway inhibitor; TFPIK36I, full-length TFPI with Lys at position 36 mutated to Ile; MES, 4-morpholineethanesulfonic acid

  • Despite a significant contribution of the substrate-membrane interaction to the perceived affinity of VIIa/TF-PCPS for factor X, the overall process can be adequately described by the Henri-Michaelis-Menten equation in a reaction in which Xa acts as a product inhibitor with affinity comparable with that of the substrate [41]

Read more

Summary

Introduction

The activation of factor X by VIIa/TF and the Xa-dependent inhibition of the enzyme complex by tissue factor pathway inhibitor (TFPI) are considered primary steps in the initiation of coagulation. These studies have been used as a formal basis to provide a global kinetic analysis and full accounting for active Xa and IXa␤ formation by VIIa/TF at physiologic concentrations of substrates and in the presence of the inhibitors TFPI and AT.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call